مباشر

FierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target FierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer FierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapy FierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia FierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reports Lonza NewsSimulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus Lonza NewsSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com Lonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com BioWorldJapanese researchers report new μ-opioid receptor antagonists BioWorldIncyte discloses new TYK2 and/or JAK1 inhibitors BioWorldInsilico Medicine divulges new NLRP3 inflammasome inhibitors BioWorldNeolaia synthesizes new CD38 inhibitors

Cell ٢٥ نوفمبر ٢٠٢٥

Shank3 oligomerization governs material properties of the postsynaptic density condensate and synaptic plasticity

Publication date: 13 November 2025Source: Cell, Volume 188, Issue 23Author(s): Bowen Jia, Zeyu Shen, Shihan Zhu, Jingguo Huang, Zhitao Liao, Shuaizhu Zhao, Hao...

Publication date: 13 November 2025Source: Cell, Volume 188, Issue 23Author(s): Bowen Jia, Zeyu Shen, Shihan Zhu, Jingguo Huang, Zhitao Liao, Shuaizhu Zhao, Hao Li, Shiwen Chen, Yang Xu, Yu Wang, Haitang Peng, Guanhua Bai, Youming Lu, Penger Tong, Wucheng Tao, Mingjie Zhang